Table 1.
Results before and after implementation of the clinical pathway
| Outcome | Before implementation (n=86) | After implementation* (n=50) | p Value† |
|---|---|---|---|
| BMD tests | 10 (12) | 32 (64) | <0.001 |
| Normal bone | 1 (1) | 6 (12) | |
| Osteopenia | 5 (6) | 15 (30) | |
| Osteoporosis | 4 (5) | 11 (22) | |
| Planned osteoporotic consultation (PCO) | 12 (14) | 40 (80) | <0.001 |
| Orthopaedics | 0 | 6 (12) | 0.002 |
| Geriatrics | 4 (5) | 15 (30) | <0.001 |
| Reumatology | 8 (9) | 19 (38) | <0.001 |
| Endocrinology | 0 | 0 | N/A |
| Appropriate osteoporosis management | |||
| Calcium and vitamin D | 26 (30) | 34 (68) | <0.001 |
| Antiosteoporotic drug | 9 (11) | 19 (38) | <0.001 |
Values are n (%).
*36 patients did not complete the pathway.
†p Values from Fisher’s exact test.
BMD, bone mineral density; N/A, not applicable.